WVE
WVE
Wave Life Sciences, Inc.
$3.17
+1.28% 2026-10-19
Healthcare
WVESPY
1W
-3.4%
1M
-27.1%
3M
-44.7%
6M
-58.2%
YTD
-81.4%
1Y
-59.4%
Grades vs sector
Momentumno data–
Momentum
no data
Percentile within its GICS sector across the S&P 1500.
Growthno data–
Growth
no data
Percentile within its GICS sector across the S&P 1500.
Valueno data–
Value
no data
Percentile within its GICS sector across the S&P 1500.
Profitabilityno data–
Profitability
no data
Percentile within its GICS sector across the S&P 1500.
Revisionsno data–
Revisions
no data
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 3 live models right now.
Momentum Top 15
not ranked (outside this model's universe or screens)
Quality Growthnot ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
Key stats
Market cap$624.6M
P/E (trailing)–
P/E (forward)-2.7
52-week range3.04 – 21.73
Revenue growth (YoY, latest qtr)-73.9%
Dividend yield0.00%
Analyst consensusStrong Buy (20)
Mean price target$17.22 (+443%)
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
▼Piotroski F-score3/9
▼Altman Z-0.2 (distress)
▲Analyst target+443% (20 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta -1.43 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs sector
Forward EPS $-1.17 vs trailing $-1.08. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
–
Operating margin
-333.4%
FCF margin
-295.5%
Net margin
-309.7%
Return on equity
-44.6%
Return on invested capital
-284.7%
Net debt / EBITDA
–
Current ratio
10.0×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 3/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score -0.2 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$17
+443%
Analysts
20
Strong Buy
Range
$8–$42
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $42.7M | $-204.4M | $-188.2M |
| 2024 | $108.3M | $-97.0M | $-152.0M |
| 2023 | $113.3M | $-57.5M | $-20.5M |
| 2022 | $3.6M | $-161.8M | $-129.1M |
| 2021 | $41.0M | $-122.2M | $-89.6M |
| 2020 | $20.1M | $-149.9M | $-117.3M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +127.1%.
Earnings
Next report: 2026-11-09 · before open · EPS est -0.32
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | -0.30 | -0.34 | -14.4% |
| 2026-04-28 | -0.31 | -0.13 | +58.5% |
| 2026-02-26 | -0.26 | -0.30 | -13.5% |
| 2025-11-10 | -0.30 | -0.32 | -8.2% |
| 2025-07-30 | -0.28 | -0.31 | -9.0% |
| 2025-05-08 | -0.26 | -0.29 | -13.5% |
| 2025-03-04 | -0.22 | 0.27 | +220.0% |
| 2024-11-12 | -0.30 | -0.47 | -54.5% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $2.3M | -73.9% |
| 2026-03-31 | $38.2M | – |
| 2025-12-31 | $17.2M | – |
| 2025-09-30 | $7.6M | – |
| 2025-06-30 | $8.7M | – |
Analyst actions
William Blair
2026-10-16 · init
→ OutperformUBS
PT $11
2026-10-15 · init
→ BuyPT $11
Ladenburg Thalmann
PT $10
2026-10-01 · init
→ BuyPT $10
JP Morgan
2026-09-23 · down
Overweight → NeutralMizuho
PT $23
2026-08-04 · main
Outperform → OutperformPT $23
Citigroup
PT $19
2026-07-31 · main
Buy → BuyPT $19
Insider trades
Rawcliffe Adrian
$67.2K
Director · 2026-08-12
SELL$67.2K
Wagner Heidi L
$42.1K
Director · 2026-08-11
SELL$42.1K
Takanashi Ken
$23.2K
Director · 2026-08-11
SELL$23.2K
Tan Aik Na
$2.6K
Director · 2026-08-11
SELL$2.6K
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
News
Wave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026
GlobeNewswire · 23h ago
Wave Life Sciences (WVE) Stock Fair Value Moves Lower As Analysts Cut Growth Views
Simply Wall St. · Oct 17
UBS Initiates Wave Life Sciences at Buy With $11 Price Target
MT Newswires · Oct 15
GSK (LSE:GSK) Following Its ADS Filing And The Case For Undervaluation
Simply Wall St. · Oct 14
Alnylam Pharmaceuticals (ALNY) vs. IONS and ARWR: Can Pipeline Growth Restore Confidence After the Guidance Cut?
Insider Monkey · Oct 14
Wave Life Sciences to Present at Chardan’s 10th Annual Healthcare Conference
GlobeNewswire · Oct 13
GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
Simply Wall St. · Oct 07
Lilly, Foghorn part ways; Wave’s FDA-approved plans
BioPharma Dive · Oct 01
Stats refreshed 2026-10-19 19:03:17 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic StrategiesSystematic equity research and model portfolios.Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.